Andere talen Ultragenyx Pharmaceutical Inc.

Aandelen

RARE

US90400D1081

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
43,85 ^USD	-0,97%		+1,08%	-8,30%

23/04	ULTRAGENYX PHARMACEUTICAL INC. : RBC Capital Markets herhaalt koopadvies	ZM
15/04	Transcript : Ultragenyx Pharmaceutical Inc. - Special Call

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update	25/04
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - April 19, 2024	22/04
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	19/04
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	15/04
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology 2024 Annual Meeting	15/04
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	15/04
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	15/04
Sector Update: Health Care Stocks Advance Premarket Monday	15/04
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	15/04
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	15/04
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	12/04
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting	12/04
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	25/03
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22/03
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22/03
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing	12/03
Ultragenyx to Participate at Investor Conferences in March	27/02
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	26/02
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	23/02
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	23/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ultragenyx Pharmaceutical Inc.

Aandelen

RARE

US90400D1081

Andere talen

Filters